Skip to content

Study · Case report or series · n = 1 · 2022

3 results

PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9624642 (opens in a new tab)PepBankPUB-97371876
Read at sourceSource pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A man with T2D taking dulaglutide developed necrotizing pancreatitis with hypertriglyceridemia after alcohol intake.

    In plain wordsA man taking dulaglutide developed severe pancreatitis after alcohol intake and had very high blood fats.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNecrotizing pancreatitis
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Labs and imaging were consistent with acute necrotizing pancreatitis with elevated lipase (502 U/L), elevated triglycerides (TG) (3,480 mg/dL), and CT abdomen/pelvis showing focal hypoattenuation/edema of the pancreatic head with surrounding fat stranding.
    3 context sentences
    Summary · context
    A 46-year-old man with type 2 diabetes mellitus, hyperlipidemia, and depression presented with one day history of severe right upper quadrant abdominal pain, nausea, and non-bloody, non-bilious vomiting.
    Summary · context
    He reported that he had drank one bottle of sparkling wine the day prior but denied drinking regularly.
    Summary · context
    Review of his medications was notable for dulaglutide for management of his diabetes.
  2. 02HumanCase report or seriesSafety outcome

    A man taking dulaglutide had elevated lipase during necrotizing pancreatitis.

    In plain wordsA man taking dulaglutide had elevated pancreatic enzyme levels during pancreatitis.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableElevated lipase
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Lipase
    502 U/L
    during pancreatitis

    Source sentences

    Summary
    Labs and imaging were consistent with acute necrotizing pancreatitis with elevated lipase (502 U/L), elevated triglycerides (TG) (3,480 mg/dL), and CT abdomen/pelvis showing focal hypoattenuation/edema of the pancreatic head with surrounding fat stranding.
    1 context sentence
    Summary · context
    Review of his medications was notable for dulaglutide for management of his diabetes.
  3. 03HumanCase report or seriesSafety outcome

    A man taking dulaglutide had markedly elevated triglycerides during necrotizing pancreatitis.

    In plain wordsA man taking dulaglutide had very high blood fats during pancreatitis.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableElevated triglycerides
    Study

    n = 1

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Triglycerides
    3480 mg/dL
    during pancreatitis

    Source sentences

    Summary
    Labs and imaging were consistent with acute necrotizing pancreatitis with elevated lipase (502 U/L), elevated triglycerides (TG) (3,480 mg/dL), and CT abdomen/pelvis showing focal hypoattenuation/edema of the pancreatic head with surrounding fat stranding.
    1 context sentence
    Summary · context
    Review of his medications was notable for dulaglutide for management of his diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.